Jane Wilkinson is the CEO and President of CANCollaborate, a non-profit 501(c)(3) that is dedicated to fostering communication, cooperation and collaborations among researchers and institutions with the goal of accelerating treatments and cures.
She is an advisor and board member to several rare cancer foundations including The Rare Cancer Research Foundation, CureMEC, Brave Like Gabe, Alliance for Rare Cancer and the Cancer Patient Lab – she is committed to creating a collaborative rare cancer research community.
Jane has over 25 years of scientific operations and alliance management experience in creating and delivering complex scientific goals. Jane’s scientific career began at the Wellcome Trust Sanger Genome Center, UK where she worked closely with Sir John Sulston on the C.elegans genome project. She was an early leader on the Human Genome Project, leading the Chromosome 1 initiative. She led a new directive in plant genomics for Monsanto Company.
Jane worked on various initiatives at the Broad Institute for eighteen years as the Senior Director for Genomics Alliances. She created and led many projects including a new whole genome approach to the Mouse Genome Project as well as collaborative initiatives across Cancer, Mendelian, Infectious and Common Diseases.
Most recently, Jane was the Executive Director of the MIT Koch Institute for Integrative Cancer Research where her focus was on creating scientific collaborations and external relationships with clinical, commercial, government and academic partners.
